Obesity-related subfertility is an increasingly recognized concern. Pharmacotherapies (particularly glucagon-like peptide 1 receptor agonists and combination therapies), alongside lifestyle intervention, enable meaningful and sustainable weight loss in people with and without type 2 diabetes mellitus. Weight loss can benefit sperm parameters, but the optimal amount and rate of weight loss requires further study.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Papanikolaou, N., Luo, R. & Jayasena, C. N. Fertility considerations in hypogonadal men. Endocrinol. Metab. Clin. North Am 51, 133–148 (2022).
Chambers, T. J. G. & Richard, R. A. The impact of obesity on male fertility. Hormones 14, 563–568 (2015).
Venigalla, G. et al. Male obesity: associated effects on fertility and the outcomes of offspring. Andrology 13, 64–71 (2025).
Andersen, E. et al. Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. Hum. Reprod. 37, 1414–1422 (2022).
Sharma, A. et al. Improvements in sperm motility following low- or high-intensity dietary interventions in men with obesity. J. Clin. Endocrinol. Metab. 109, 449–460 (2024).
Melson, E., Ashraf, U., Papamargaritis, D. & Davies, M. J. What is the pipeline for future medications for obesity? Int. J. Obes. 49, 433–451 (2025).
Carette, C. et al. Changes in total sperm count after gastric bypass and sleeve gastrectomy: the BARIASPERM prospective study. Surg. Obes. Relat. Dis. 15, 1271–1279 (2019).
Cannarella, R. et al. Is there a role for glucagon-like peptide-1 receptor agonists in the treatment of male infertility? Andrology 9, 1499–1503 (2021).
La Vignera, S., Condorelli, R. A., Calogero, A. E., Cannarella, R. & Aversa, A. Sexual and reproductive outcomes in obese fertile men with functional hypogonadism after treatment with liraglutide: preliminary results. J. Clin. Med. 12, 672 (2023).
Gregorič, N., Šikonja, J., Janež, A. & Jensterle, M. Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes Obes. Metab. 27, 519–528 (2025).
Acknowledgements
The authors acknowledge the support of the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre and NIHR Imperial Biomedical Research Centre.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.P. has received honoraria for lectures from Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Johnson and Johnson and has received research grants from Novo Nordisk, Novo Nordisk UK Research Foundation and Academy of Medical Sciences/Diabetes UK. C.N.J. received research-led grants from Logixx Pharma. T.Y. is supported by the NIHR Leicester BRC and has received funding from Astra Zeneca for an investigator-initiated project. M.J.D. has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, has attended advisory boards for Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Sanofi, Zealand Pharma and Regeneron and has acted as a speaker for AstraZeneca and Boehringer Ingelheim. M.J.D. has received grants from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Morrison, A.E., Papamargaritis, D., Jayasena, C.N. et al. Can obesity pharmacotherapy be used to manage male infertility?. Nat Rev Endocrinol 21, 518–520 (2025). https://doi.org/10.1038/s41574-025-01151-7
Published:
Issue date:
DOI: https://doi.org/10.1038/s41574-025-01151-7
